Affairs (HFE–1), Food and Drug Administration, Parklawn Bldg., 5600 Fishers Lane, rm. 16–85, Rockville, MD 20857, 301–827–4404, FAX 301–827–3052, or e-mail ''clewis@bangate.fda.gov''.

SUPPLEMENTARY INFORMATION: The purpose of this meeting is to provide an opportunity for consumers to discuss their concerns and thereby participate in agency decision and policymaking on key health care and consumer protection issues. To register for the meeting and obtain directions, please call, fax, or e-mail the contact person (address above). Include the name, title, telephone and fax numbers of the person attending, and the name of the organization being represented.

If special accommodations are required due to a disability, please contact Carol M. Lewis at least 7 days in advance of the meeting.

Dated: August 8, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–21573 Filed 8–13–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of public advisory committees of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committees: Joint meeting of the Nonprescription Drugs Advisory Committee and Pulmonary-Allergy Drugs Advisory Committee.

General Function of the Committees: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 19, 1997, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Andrea G. Neal or Leander B. Madoo, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), codes 12541 and 12545. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committees will jointly consider new drug application (NDA) 20–840, Beconase® Allergy Nasal Spray (belcomethasone dipropionate 0.042%, monohydrate, Glaxo Wellcome, Inc.) for over-the-counter treatment and prevention of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 5, 1997. Oral presentations from the public will be scheduled between approximately 8:30 a.m. to 9:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 5, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 7, 1997.

William B. Schultz,

Acting Lead Deputy Commissioner for the Food and Drug Administration.

[FR Doc. 97–21571 Filed 8–13–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Nonprescription Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 18, 1997, from 8:30 a.m. to approximately 5 p.m.

Location: Holiday Inn, The Ballroom, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Andrea G. Neal, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

Agenda: The Committee will discuss issues relating to the labeling and dosing of over-the-counter (OTC) pediatric analgesic/antipyretic drug products. The Committee will discuss topics such as: (1) What is an appropriate lower age limit for the dosing of OTC analgesic/antipyretic drug products; and (2) the safety implications of the OTC availability of children's analgesic/antipyretic suspension products and double concentrated infant drops with overlapping age directions.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 12, 1997. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 12, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C., app. 2).

Dated: August 7, 1997.

William B. Schultz,

Acting Lead Deputy Commissioner for the Food and Drug Administration.

[FR Doc. 97–21574 Filed 8–13–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.